



#startupoftheday 101- Onward Health

24 January 2022 | Features

Building diagnostic tools for Histopathologists and Radiologists

Inception- 2017

Location- Hyderabad

Domain- Diagnostics

Founders- Dinesh Koka, Vikas Ramachandra and Dr Lata Kini

Total team strength- 17

Total funds raised- Rs 7.4 crore

Investors- CIIE-IIMA, IIITH Foundation, Lets Venture, Vijay Kedia, BVR Mohan Reddy, Madhusudan Peshwa (Incubated under Incubation Programme for Healthcare Startups at IIMB-NSRCEL)

Revenue generated since inception- Rs 10 lakh per month

Key Highlights-

- Onward Assist is the Predictive Analytics platform from Onward Health
- Has 5 AI algorithms in cancer pathology which are in fished state and available for use in academic and research use
- In 2021, received provisional patent in pathology AI imaging pipeline
- Winner of Jancare Grand Challenge in 2021
- Winner of Top 15 AI GameChangers (Microsoft-Deloitte-Nasscom) in 2021
- Winner of Amazon AI Conclave in 2021
- Winner of Nasscom Emerge 50 in 2020
- Winner of Microsoft EmergeX in 2020
- Winner of Startup Award – NHA-Ayushman Bharat in 2019
- Winner of RICH Cancer Innovation Challenge in 2018
- Winner of Best Technology Innovation (HYSEA 2018)
- Currently generating revenues for workflow products including Telepathology as well as integrated workflow for RTPCR reporting
- To commercialise the cancer pathology AI tools in diagnostics from March 2022
- Completed 2 pilots in the US for Digital Pathology software for diagnostics as well as for academic applications
- Rolling out the commercial application in the US

Founder Speaks-

“We are seeing increasing adoption of technology in healthcare - this will positively impact our focus areas as well, in encouraging adoption digitisation and software in pathology diagnosis as well. Our work with pharma and drug research also has indicated that AI will also be increasingly adopted in the pharma domain. Cancer pathology in India faces a huge shortage of expert pathologists with expertise from reporting on cancer biopsies - private and public healthcare providers will prefer a full-stack solution which combines an effective telepathology software with low cost hardware as well as advanced AI based analytics.”

